Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
Orexo AB (ORXOY) announces that it expects to file a New Drug Application for its Opioid overdose rescue drug OX124 with the US Food and Drug Administration by mid-2022.OX124 is expected to follow the FDA's standard submission and review timelines, as the FDA did not grant Fast...
Orexo expects FDA filing of OX124 mid 2022 - OX124 is designed to reverse the effect of the most powerful synthetic opioids - Synthetic opioids are behind the majority of fatal overdoses in the US, a development expected to increase due to Covid-19 - New Drug Application...
Orexo AB (ORXOY): Q4 GAAP EPS of -SEK1.45.Revenue of SEK159.2M (-33.1% Y/Y)Press Release For further details see: Orexo AB reports Q4 results
Orexo Q4 2020, incl. Full Year Report ZUBSOLV® stable and strong EBIT, despite challenging market due to COVID-19 PR Newswire UPPSALA, Sweden , Jan. 28, 2021 /PRNewswire/ -- Q4 2020 highlights Total net revenues of SEK 159.2 m (238.1 la...
Orexo strengthens IP rights for overdose rescue drug OX124 - Patent protection until 2039 - Previous human pharmacokinetic (PK) study showed significantly better PK profile when compared to market leading product PR Newswire UPPSALA, Sweden , Jan. 27, 2021 ...
Orexo AB (ORXOY) has been issued an additional new US patent (Patent No. 10,874,661) for Orexo's Zubsolv sublingual buprenorphine and naloxone tablet ((CII)) for the treatment of opioid use disorder.The new patent expires in September 2032 and further strengthen...
Orexo announces new US patent for ZUBSOLV® PR Newswire UPPSALA, Sweden , Dec. 30, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®...
Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV® in Europe UPPSALA, Sweden , Dec. 7, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) has entered into an exclusive licensing agreement with Accord Healthcare, ...
Accenture, Orexo Team to Offer Digital Therapeutics through INTIENT™ Platform PR Newswire NEW YORK and MORRISTOWN, N.J., Nov. 16, 2020 NEW YORK and MORRISTOWN, N.J. , Nov. 16, 2020 /PRNewswire/ -- Accenture (NYSE: ACN) has helped the U.S. subsidiar...
Correction notice of press release - Q3 2020 Interim Report - ZUBSOLV® guiding 2020 PR Newswire UPPSALA, Sweden, Nov. 4, 2020 UPPSALA, Sweden , Nov. 4, 2020 /PRNewswire/ -- (STO:ORX) (OTCQX:ORXOY) In connection with the publication of the Interim Rep...
News, Short Squeeze, Breakout and More Instantly...
Orexo Q2 2024 Interim Report PR Newswire UPPSALA, Sweden , July 17, 2024 /PRNewswire/ -- Making progress, while the OX124 review time extended Q2 2024 highlights Total net revenues of SEK 154.0 m (157.7) EBITDA of SEK 5.0 m (5.6)...
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose PR Newswire UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis PR Newswire UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the...